<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02002182</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 13-1411</org_study_id>
    <nct_id>NCT02002182</nct_id>
  </id_info>
  <brief_title>ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive Oropharyngeal Cancer</brief_title>
  <official_title>Window of Opportunity Trial of Neoadjuvant ADXS 11-001 Vaccination Prior to Robot -Assisted Resection of HPV-Positive Oropharyngeal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Sikora</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Advaxis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some cancers may be related to an infection with a virus, such as the Human Papilloma Virus
      (HPV). HPV related Oropharyngeal cancer (HPVOPC) accounts for 80% of oropharynx cancer cases
      in the United States. HPVOPC has better prognosis than patients with HPV negative oropharynx
      cancer. In many hospitals, the standard of care treatment for oropharyngeal cancer is surgery
      and/or radiotherapy with or without chemotherapy. While chances of survival for most patients
      with HPVOPC is very good, current treatments are associated with short- and long-term side
      effects which can be severe. In pre-clinical research using animal models of cancer,
      vaccination targeting the HPV virus has been found to cause tumor regression. Thus,
      approaches which target the unique characteristics of HPV-infected cancer cells, such as
      therapeutic vaccination, are attractive strategies for potentially reducing radiotherapy and
      chemo radiotherapy regimens (and thus decreasing toxicity) and enhancing long-term disease
      control.

      The purpose of this study is to see if an experimental vaccine, ADXS11-001, is effective in
      stimulating the body's defense system against HPV-positive oropharyngeal squamous cell
      carcinoma before transoral (through the mouth) surgery. The experimental product ADXS11-001
      uses a live strain of the Listeria monocytogenes (Lm) bacteria that has been genetically
      modified such that the risk of getting an infection is significantly reduced. Several
      research studies have already been conducted with ADXS11-001 in men and women with cancer. So
      far, approximately 722 doses of ADXS11-001 have been given to 290 patients with HPV
      associated cancers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an investigator-initiated prospective clinical study of patients with stage I-IV
      squamous cell carcinoma of the oropharynx (OPSCC) who are to undergo ablative transoral
      robotic surgery (TORS).

      There is a vaccination group and a control group in this study.

      Subjects in the control group will not receive the vaccination and will only be followed
      after TORS surgery for additional research blood tests to measure how their immune system is
      working.

      Subjects in the vaccination group will receive two vaccinations prior to surgery. The first
      dose will be about 33 days before surgery, and the second will be about 14 days before
      surgery.

      Participation in this study will also include allowing the research team to take several
      blood samples from the subject at various times before, during, and after treatment for
      his/her cancer.

      Vaccination subjects will be monitored closely after treatment and includes 6 months of oral
      antibiotics.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">August 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in HPV E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses</measure>
    <time_frame>baseline and Day 15</time_frame>
    <description>The primary endpoint will be the change in HPV E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses in the peripheral blood at time of surgery, with respect to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in HPV E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses</measure>
    <time_frame>baseline and Day 25</time_frame>
    <description>The primary endpoint will be the change in HPV E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses in the peripheral blood at time of surgery, with respect to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in HPV E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>The primary endpoint will be the change in HPV E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses in the peripheral blood at time of surgery, with respect to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in HPV E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses</measure>
    <time_frame>baseline and 6 months</time_frame>
    <description>The primary endpoint will be the change in HPV E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses in the peripheral blood at time of surgery, with respect to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>change in HPV E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>The primary endpoint will be the change in HPV E6/E7-specific CD8+ cytotoxic lymphocyte (CTL) responses in the peripheral blood at time of surgery, with respect to baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Baseline</time_frame>
    <description>To evaluate the tolerability, safety, and nature and degree of toxicity of ADX11001 by the numbers of patients with dose limiting toxicities (DLTs) and adverse events as assessed by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Day 15</time_frame>
    <description>To evaluate the tolerability, safety, and nature and degree of toxicity of ADX11001 by the numbers of patients with dose limiting toxicities (DLTs) and adverse events as assessed by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>Day 25</time_frame>
    <description>To evaluate the tolerability, safety, and nature and degree of toxicity of ADX11001 by the numbers of patients with dose limiting toxicities (DLTs) and adverse events as assessed by the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine induced HPV E6/E7specific CD8+ CTL responses</measure>
    <time_frame>baseline and 2 weeks</time_frame>
    <description>Vaccine induced HPV E6/E7specific CD8+ CTL responses in the blood at 2, 4, and 6 weeks and 3, 6, and 12 months after surgery, with respect to baseline levels, in vaccinated patients and unvaccinated controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine induced HPV E6/E7specific CD8+ CTL responses</measure>
    <time_frame>baseline and 4 weeks</time_frame>
    <description>Vaccine induced HPV E6/E7specific CD8+ CTL responses in the blood at 2, 4, and 6 weeks and 3, 6, and 12 months after surgery, with respect to baseline levels, in vaccinated patients and unvaccinated controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine induced HPV E6/E7specific CD8+ CTL responses</measure>
    <time_frame>baseline and 6 weeks</time_frame>
    <description>Vaccine induced HPV E6/E7specific CD8+ CTL responses in the blood at 2, 4, and 6 weeks and 3, 6, and 12 months after surgery, with respect to baseline levels, in vaccinated patients and unvaccinated controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine induced HPV E6/E7specific CD8+ CTL responses</measure>
    <time_frame>baseline and 3 months</time_frame>
    <description>Vaccine induced HPV E6/E7specific CD8+ CTL responses in the blood at 2, 4, and 6 weeks and 3, 6, and 12 months after surgery, with respect to baseline levels, in vaccinated patients and unvaccinated controls.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vaccine induced HPV E6/E7specific CD8+ CTL responses</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Vaccine induced HPV E6/E7specific CD8+ CTL responses in the blood at 2, 4, and 6 weeks and 3, 6, and 12 months after surgery, with respect to baseline levels, in vaccinated patients and unvaccinated controls.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Squamous Cell Carcinoma of the Head and Neck</condition>
  <condition>HPV Positive Oropharyngeal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Treatment-Vaccine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two vaccinations with ADXS11-001 (ADXS-HPV) will be given at a dose of 1x10^9 cfu intravenously. The drug will be given as a 500ml infusion over 60 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Observational control group treated with standard of care therapy only</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ADXS11-001 (ADXS-HPV)</intervention_name>
    <description>ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.</description>
    <arm_group_label>Treatment-Vaccine Group</arm_group_label>
    <other_name>ADXS11-001</other_name>
    <other_name>ADXS-HPV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has newly-diagnosed, biopsy proven squamous cell carcinoma of Stage I-IV
             (T1-3, N0-2b) of the oropharynx.

          -  The patient's tumor is HPV positive by PCR or ISH assay of tumor biopsy.

          -  The patient is able/eligible to undergo treatment with transoral robotic surgery
             (TORS) with or without neck dissection and with or without adjuvant radiation therapy
             or chemoradiation.

          -  The patient is able to understand and give informed consent.

          -  The patient is at least 18 years old.

          -  The patient's ECOG performance status is &lt;/= 2.

        Exclusion Criteria:

          -  The patient has had prior head and neck squamous cell carcinoma (HNSCC), with the
             exception of superficial cutaneous basal cell or squamous cell carcinomas.

          -  The patient has active cancer in another part of the body, with the exception of
             superficial cutaneous basal cell or squamous cell carcinomas

          -  If a cancer survivor, the disease free interval is less than 3 years, with the
             exception of superficial cutaneous basal cell or squamous cell carcinomas.

          -  If a cancer survivor the patient received prior systemic chemotherapy or radiotherapy

          -  If prior standard-of-care pre-treatment biopsy is inadequate for analysis by
             immunohistochemistry, and the patient is unwilling to undergo an additional biopsy
             procedure.

          -  The patient is a prisoner.

          -  The patient has a psychiatric illness or developmental delay which would interfere
             with understanding of the study and provision of informed consent.

          -  The patient has previously received definitive surgical, radiation, or chemoradiation
             treatment for HNSCC.

          -  The patient has a history of HIV or other known cause of immunosuppression, or is
             actively taking immunosuppressive medications due to organ transplantation, rheumatoid
             disease, or other medical conditions.

          -  Patient is allergic to naproxen or Ibuprofen.

          -  The patient has a history of liver disease.

          -  The patient has a contraindication (e.g. sensitivity/allergy) to both
             trimethoprim/sulfamethoxazole and ampicillin.

          -  The patient has implanted medical device(s) that pose a high risk for colonization
             and/or cannot be easily removed (e.g., prosthetic joints, artificial heart valves,
             pacemakers, orthopedic screw(s), metal plate(s), bone graft(s), or other exogenous
             implant(s)). NOTE: More common devices and prosthetics which include arterial and
             venous stents, dental and breast implants and venous access devices (e.g. Port-a-Cath
             or Mediport) are permitted.

          -  Patients who are receiving or may receive future treatment with PI3K or TNFÎ±
             inhibitors.

          -  Patients who have undergone a major surgery, including surgery for a new artificial
             implant and/or device, within 6 weeks prior to the initiation of ADXS11-001 treatment.
             Sponsor must be consulted prior to enrolling subjects on the study who recently had a
             major surgery or have new artificial implant, and/or devices.

          -  Patients who have a history of listeriosis or prior ADXS11-001 therapy.

          -  Patients with a known allergy to any component of the study treatment formulations.

          -  Pregnancy. The effects of this vaccine on the developing human fetus are unknown. For
             this reason women of child-bearing potential and men must use two forms of
             contraception (i.e., barrier contraception and one other method of contraception) at
             least 4 weeks prior to study entry, for the duration of study participation, Should a
             woman become pregnant or suspect she is pregnant while participating in this study,
             she should inform her treating physician immediately.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew G Sikora, MD PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brett Miles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jigneshkumar Patel</last_name>
    <phone>713-798-8541</phone>
    <email>Jigneshkumar.patel@bcm.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brett Miles, MD</last_name>
      <email>brett.miles@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Alex Park, MD</last_name>
      <phone>(212) 241-4282</phone>
      <email>Alex.park@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>Brett Miles, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jun Zhang, MD</last_name>
      <phone>713-798-3750</phone>
      <email>junz@bcm.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2013</study_first_submitted>
  <study_first_submitted_qc>December 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2013</study_first_posted>
  <last_update_submitted>April 23, 2018</last_update_submitted>
  <last_update_submitted_qc>April 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Andrew Sikora</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>oropharynx</keyword>
  <keyword>squamous cell carcinoma</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>transoral robotic surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

